1. Home
  2. CXAI vs GDTC Comparison

CXAI vs GDTC Comparison

Compare CXAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.18

Market Cap

10.2M

Sector

Technology

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.00

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXAI
GDTC
Founded
N/A
2018
Country
United States
Singapore
Employees
35
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CXAI
GDTC
Price
$0.18
$1.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.3M
7.2K
Earning Date
05-19-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$33.54
$5.37
Revenue Next Year
$116.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.73
52 Week High
$1.45
$3.68

Technical Indicators

Market Signals
Indicator
CXAI
GDTC
Relative Strength Index (RSI) 41.01 43.57
Support Level $0.15 $0.97
Resistance Level $0.25 $1.11
Average True Range (ATR) 0.03 0.04
MACD -0.01 -0.00
Stochastic Oscillator 30.08 24.04

Price Performance

Historical Comparison
CXAI
GDTC

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: